CervoMed (NASDAQ: CRVO) announces positive dementia drug trial data

CervoMed Inc. (NASDAQ: CRVO) stock rose 30% after the company reported positive 32-week data from its RewinD-LB trial showing that its experimental drug neflamapimod significantly slowed clinical progression in patients with dementia with Lewy bodies (DLB).

The Boston-based clinical-stage company announced that patients treated with neflamapimod demonstrated a 54% risk reduction in clinically significant worsening compared to control at Week 32, as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB). This risk reduction improved to 64% among patients with minimal evidence of Alzheimer’s Disease co-pathology.

Additionally, patients receiving the treatment showed a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP), a biomarker associated with neurodegeneration.

The trial results were presented at the Alzheimer’s Association International Congress 2025 on Sunday. CervoMed noted that the drug demonstrated comparable safety and tolerability profiles with no new safety signals identified during the extension phase.

“Reducing the risk of a 1.5-point worsening over 32 weeks on the CDR-SB by more than 50% would likely represent a clinically meaningful slowing of clinical progression at a level that patients and caregivers would notice in day-to-day function,” said Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center and an investigator who presented the results.